Cullinan Oncology, Inc. (CGEM) Misses Q2 EPS by 25c

Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q2 EPS of ($1.07), $0.25 worse than the analyst estimate of ($0.82).

For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Italy’s Meloni said to consider April election amid falling support
• EHang selected for Hong Kong low-altitude economy sandbox trial